OSR Holdings Restructures Cancer Drug Deal to Maximize Direct Shareholder Returns

New York, Monday, 23 March 2026.
Today’s strategic restructuring of OSR Holdings’ cancer drug agreement routes up to $815 million in potential payments directly to the parent company, immediately triggering a 20% stock surge.